By 2020, China will be the #2 pharmaceutical market in the world and health care spending in China will keep increasing in the foreseeable decade. In order to adapt to these changes, the Chinese government initiated regulatory reform in 2015 to improve Chinese patient benefits by creating a friendly pharmaceutical development environment, solve the drug lag and encourage innovation. These systematic and fundamental changes are already happening in China.
It is suggested that all sponsors reconsider their China strategy by understanding the opportunity and challenges that China regulatory reform brings.
Please join PAREXEL around the discussion of the following:
- China regulatory system
- China regulatory reform landscape
- Foreign data acceptance of CFDA
- CFDA communication